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We prospectively evaluated the 5-year predictive values of adding high-risk human papillomavirus (hrHPV) testing to cytology for the
detection ofXcervical intraepithelial neoplasia (CIN)3 lesions in a population-based cohort of 2810 women. At baseline, nine (0.3%)
women had prevalent lesions XCIN3, all being hrHPV positive. After 5 years of follow-up, four (6.5%) of the 62 hrHPV-positive
women with normal cytology developed lesions XCIN3, vs only one (0.05%) of the 2175 hrHPV-negative women with normal
cytology. High-risk human papillomavirus testing or combined screening revealed a much higher sensitivity, at the cost of a small
decrease in specificity, and a higher negative predictive value for the detection of lesions XCIN3 till the next screening round (5
years) than cytology alone.
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Cervical screening by cytology is known to yield a substantial
proportion of both false-positive and false-negative smears. Since
infection with high-risk human papillomavirus (hrHPV) is
considered to be the cause of cervical carcinoma, it has been
suggested that adding hrHPV testing to cervical screening might
improve screening in terms of reducing false-positive and false-
negative smears (Rozendaal et al, 2000; Cuzick et al, 2003).
However, long-term data are needed before hrHPV testing can be
implemented in population-based cervical screening. Here, we
present for the first time the prospective long-term (5 years)
predictive values of routine hrHPV testing in population-based
cervical screening in The Netherlands.
MATERIAL AND METHODS
A cohort of 3170 women (mean age 45 years; range 29–61 years)
was enrolled from March 1995 till October 1998 by 60 general
practitioners in the small district of Amstelveen, The Netherlands.
In all, 194 women were excluded because of abnormal cervical
cytology and/or histology during 2 years preceding the intake, 159
women because of a negative b-globin PCR test, and seven women
because of inadequate cytology, leaving 2810 women for analysis.
Cytological screening was performed according to the CISOE-A
classification, routinely used in cervical screening in The Nether-
lands, and the referral policy was according to the nationwide
guidelines (Bulk et al, 2004). High-risk human papillomavirus
testing was performed by GP5þ /6þ PCR-EIA, using a cocktail
probe of 14 hrHPV types, and independent of cytology results. The
hrHPV test result was blinded. Informed consent was obtained and
the study was approved by the Medical Ethics Committee of the
VU University Medical Center. The primary end point of the study
was the detection of histologically proven cervical intraepithelial
neoplasia grade 3 or cervical carcinoma (XCIN3) up to and
including the next screening round (after 5 years). Follow-up data
were retrieved from the Dutch nationwide pathology registry
(PALGA) in 2004.
Sensitivity, specificity, negative predictive value (NPV) and
positive predictive value (PPV) of cytology, cytology and hrHPV
testing combined, and hrHPV testing, for the detection of
prevalent and incident lesions XCIN3 were computed using two
by two tables. Results are presented as percentages with 95%
confidence intervals (95% CI). To determine whether any gain in
test performance from the addition of the second test (hrHPV
testing) was greater than that expected if the second test offered no
diagnostic information, expected performance characteristics for
cytology combined with a random test having the similar
prevalence as hrHPV were computed (Franco and Ferenczy, 1999).
RESULTS
Of 2810 women for analysis at baseline, 2687 (95.6%) women had
normal cytology, of whom 77 (2.9%) had a positive hrHPV test.
Among 111 (4.0%) women with borderline or mild dyskaryosis
(BMD), 16 (14.4%) women were hrHPV positive, as were 11
(91.7%) of 12 (0.4%) women with moderate dyskaryosis or worse
(4BMD). Among the 123 (5.2%) women who had abnormal
cytology, nine (7.3%) cases of prevalent lesions XCIN3 were
present (including three squamous cell carcinomas) (Table 1),
resulting in a detection rate of 0.3% lesions XCIN3 by cytology
among all 2810 women at baseline. All women with lesionsXCIN3
at baseline had a positive hrHPV test.
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The median follow-up time until histological or cytological
diagnoses was 4.6 years (range 0.1–8 years). The follow-up results
of women with normal cytology at baseline are presented in
Table 2. Of the 2687 women with normal cytology, 304 did not
have follow-up data registered in PALGA. Another 146 women
were excluded because they reached age 60 years or over and
therefore were not called for further screening, leaving 2237
(83.3%) women with normal cytology for follow-up analysis.
Among the 62 women of this cohort with an hrHPV-positive test at
baseline, four (6.5%) cases had incident lesions XCIN3. Among
the 2175 women with a negative hrHPV test, one (0.05%) lesion
XCIN3 (an adenocarcinoma) was registered within this follow-up
period. This woman with a symptomatic adenocarcinoma, who
was tested hrHPV negative by GP5þ /6þ PCR EIA twice, revealed
human papillomavirus (HPV) type 31 by E7 type-specific PCR in
the baseline and follow-up smear. This suggests viral integration
with disruption of the L1 region that is targeted by the GP5þ and
GP6þ primers. For hrHPV-positive women with normal cytology,
the relative risk to develop lesions XCIN3 in 5 years was 140.3
(95% CI; 15.9–1237.3) compared to hrHPV-negative women with
normal cytology. The overall detection rate after 5 years in this
study of lesions XCIN3 by cytology was 0.5%.
The performance characteristics of cytology, cytology and
hrHPV combined, and hrHPV testing, for the detection of lesions
XCIN3 are given in Table 3. Combined screening revealed a much
higher sensitivity, at the cost of a small decrease of specificity, and
a higher NPV at the next screening interval (after 5 years) than
cytology alone. Combined testing was more sensitive than cytology
alone (92.9 vs 64.3%, respectively; P¼ 0.065), but was less specific
(92.7 vs 95.14%, respectively; Po0.001), and had an increased NPV
(99.95 vs 99.78%, respectively; P¼ 0.109) with a similar PPV (7.0 vs
7.3%; P¼ 0.922). High-risk human papillomavirus testing alone
Table 1 Baseline histology stratified to cytological diagnosis and hrHPV status
Scc Aden. Ca CIN3 CIN2 Lesser abnormality Normal Total
Baseline cytology Baseline hrHPV n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Normal + —  — — — 77 (100) 77 (100)
 —  — — — 2610 (100) 2610 (100)
BMD + —  3 (18.8) 3 (18.8) 2 (12.5) 8 (50.0) 16 (100)
 —  — 1 (1.1) 6 (6.3) 88 (92.6) 95 (100)
4BMD + 3 (27.3)  3 (27.3) 2 (18.2) 3 (27.3) — 11 (100)
 —  — — — 1 (100) 1 (100)
Total 3 (0.1)  6 (0.2) 6 (0.2) 11 (0.4) 2784 (99.1) 2810 (100)
Scc, squamous cell carcinoma; Aden. Ca, adenocarcinoma; CIN1–3, cervical intra-epithelial neoplasia grade 1–3; lesser abnormality, CIN1 or abnormal smear; normal,
histological or cytological normal diagnoses; BMD, borderline or mild dyskaryosis (Pap 2–3a mild dyskaryosis); 4BMD, moderate dyskaryosis or worse (Pap 3a moderate
dyskaryosis or worse); FU, follow-up. Baseline histology is presented for women with BMD and 4BMD, with the annotation that for women with BMD histology was obtained
after a serial abnormal smear after 6 or 18 months. For women with normal cytology (Pap 1), the follow-up data are presented in Table 2.
Table 2 Years of follow-up of women with normal cytology stratified to final histological diagnosis
0 year 1 year 2 years 3 years 4 years 5 years 6 years 7 years 8 years Total FU
Baseline status FU n n n n n n n n n n
Normal cytology, hrHPV positive XCIN3 — 1 — — 2a 1 — — — 4
CIN2 — — — — — — — — — —
Lesser abnormality — — 1 — 2 3 — — — 6
Normal — 4 7 6 10 19 4 1 1 52
Normal cytology, hrHPV negative XCIN3 — — — — — — — 1b — 1
CIN2 — — 2 1 — — — — — 3
Lesser abnormality 1 — — 3 2 13 6 1 26
Normal 19 60 252 338 337 723 346 60 10 2145
Total 20 65 262 348 353 759 356 63 11 2237
Of the total number of 2687 women with normal cytology, 450 did not have follow-up data: 146 women of 59–61 years of age were not expected to have another cervical
screening and 304 did not have another screening because of other reasons. FU, follow-up; year(s), year(s) of follow-up; CIN, cervical intra-epithelial neoplasia;XCIN3, CIN3 or
worse; lesser abnormality, CIN1 or abnormal smear; normal, Histological or cytological normal diagnoses. aOne woman was diagnosed with squamous cell carcinoma, the other
with CIN3. bAdenocarcinoma.
Table 3 Observed performance characteristics for lesions XCIN3 for cytology, cytology+hrHPV and hrHPV testing
Sensitivity Specificity Positive predictive value Negative predictive value
Cytology 64.3 (35.6–86.0) 95.1 (94.2–96.0) 7.3 (3.9–13.3) 99.78 (99.48–99.90)
Cytology+HrHPV 92.9 (64.2–99.6)** 92.7 (91.5–93.7)* 7.0 (4.2–11.7)w 99.95 (99.74–99.99)**
HrHPV 92.9 (64.2–99.6)** 96.7 (95.9–97.4)* 14.6 (8.7–23.4)** 99.96 (99.75–99.99)**
Expected performance characteristics for cytology and a combined test, which assumes that the second test is random with the same prevalence as hrHPV (3.7%), with respect
to disease detection: sensitivity 65.6 (36.8 –86.9), specificity 91.6 (90.3 –92.6), PPV 4.4 (2.4 –8.2), NPV 99.78 (99.47–99.91); P-values for differences in performance
characteristics compared to cytology: *Pp0.05; **Pp0.1; wP40.1.
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was more sensitive than cytology alone (92.9 vs 64.3%, respec-
tively; P¼ 0.065), more specific (96.8 vs 95.1%, respectively;
P¼ 0.005), and had an increased NPV (99.96 vs 99.78%,
respectively; P¼ 0.098) and an increased PPV (14.6 vs 7.3%,
respectively; P¼ 0.085). Comparing the sensitivity and NPV of
cytology and hrHPV combined screening to cytology with a
random test, no different significance levels were revealed as when
compared to cytology alone.
DISCUSSION
Combined screening revealed a much higher sensitivity, at the cost
of a small decrease of specificity, and a higher NPV at the next
screening interval (after 5 years) than cytology alone. Cytology
alone had reasonable performance characteristics, but on adding
hrHPV testing we can achieve much better performance char-
acteristics in population-based screening.
The overall detection rate by cytology of 0.3% lesionsXCIN3 at
baseline and 0.5% after 5 years in this study is comparable to the
detection rate of lesionsXCIN3 in cervical cancer screening in The
Netherlands (Bos et al, 2002; Anttila et al, 2004). The high NPV of
the combination of a negative hrHPV test and a normal smear is in
accordance with Clavel et al (2004), who reported an NPV of 99.9%
in a partly hospital-based population, with a much shorter interval
(median 2.8 years) for women of 15–79 years of age. Sherman
reported an NPV of 99.2% for hrHPV in cervical lavage specimens
during annual screening for women of 16–94 years of age
(Sherman et al, 2003). The data are also in line with the data of
the Manchester cohort (Peto et al, 2004).
Our data are the first that were prospectively obtained in
population-based screening, with a 5-years screening interval in
women 30–60 years of age. Some methodological aspects of this
study need to be discussed. The fact that histology was not
obtained in all women might induce a verification bias in
advantage of combined screening and hrHPV testing. However,
women were followed according to current practice standards in
nationwide screening with cytology after 5 years, and in this setting
women with normal cytology are considered to be free of disease.
As indicated by the overlapping 95% CIs, the gains in sensitivity
and NPV by combined testing or hrHPV testing compared to
cytology alone were not significant (Pp0.05). This might be due to
our relatively small population with a low prevalence of lesions
XCIN3, resulting in wide 95% CIs. However, with this low
prevalence of lesions XCIN3, still a borderline significance was
reached (Pp0.1). The increase in sensitivity by combined testing
compared to cytology alone may be misleading because improve-
ments in sensitivity would be expected by adding a second test,
even if the second test performed randomly with respect to disease
identification. For this reason, expected performance character-
istics for cytology combined with a random test were computed to
determine if any gain in test performance from the addition of the
second test (hrHPV testing) was greater than that expected if the
second test offered no diagnostic information (Franco and
Ferenczy, 1999). By comparing the sensitivity and NPV of cytology
and hrHPV combined screening to cytology with a random test, no
different significance levels were revealed as when compared to
cytology alone.
Cost-effectiveness studies and modelling studies show that
cervical screening may become much more efficient in terms of
decreasing numbers of false-negative and false-positive smears, if a
test is used with a substantial higher sensitivity and long-term NPV
than conventional cytology (Canfell et al, 2004). Negative test
results in combined screening predicted that the future risk for
lesions XCIN3 was very low. The higher sensitivity for lesions
XCIN3 and the long-term NPV for lesions XCIN3 of hrHPV
testing in combination with classical cytology and of sole hrHPV
testing show that these could be such a test.
The use of hrHPV testing in cervical screening could lead to
several different screening strategies, including combined cytology
and hrHPV testing, or primary screening by hrHPV with cytology
reading only of women tested hrHPV positive. In addition, the
high sensitivity and NPV of hrHPV testing opens possibilities for
longer screening intervals with still acceptable rates of incipient
lesions. Modelling studies and confirmation of our results in larger
studies will help to clarify this discussion and to devise more
efficient cervical screening strategies.
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